Announcement: Merger of Vector Development Laboratory and Gene Vector Core
We are excited to announce the merger of the Vector Development Laboratory of the Center for Cell and Gene Therapy with the Gene Vector Core, an Institutional Advanced Technology Core.
Effective Nov. 1, 2021, the merged core, that retains the name Gene Vector Core, will provide expanded services available to all national and international investigators that combine the technologies and resources of the two facilities under a single operational organization. View a listing of the services.
The newly merged core is co-directed by Kazuhiro Oka, Ph.D. (current Gene Vector Core Director), and Corinne Sonnet, Ph.D. (Director of the former Vector Development Lab). As a support group for the BCM research community, we welcome ideas to improve services as well as to develop new viral vectors.
About the Core
The Gene Vector Core was founded in 1997 as the Adenovirus Vector Production Core. Over the years, we have extended our expertise to other popular viral vector systems. Our core has been one of BCM Advanced Technology Cores since October 2013. More recently, the Vector Development Laboratory merged with our group, and we have expanded our services to offer AAV, first-generation adenovirus (FGAd), helper-dependent adenovirus (HDAd), Lentivirus (LV), Retrovirus (RV), and G-deleted Rabies (RaV). In addition, we have a variety of supporting services available such as subcloning, plasmid preparation, viral titration, and other Quality Controls assays.
Our services are available to all national and international institutions (non-profit and profit).
There is no single viral vector system fit for all purposes. Professional consultation is provided by a group of experienced staff, dedicated to the production of viral vectors for use in basic research. We can prepare viral vectors to Good Laboratory Practice (GLP) standards. The preclinical data generated by agents produced by the GLP practice can be valuable in the later development of clinical trials in gene therapy.
To help investigators choose the optimum vector system for their proposed application, the Core has many in-stock vectors containing a range of reporters, which will provide essential information about transduction.
All our viral vectors are produced and purified following Standard Operating Procedures. Infectious titers and other quality control assays may be subject to an additional charge. The core has various expression cassettes and basic transfer vectors for expressing your genes including shRNA and gRNA. Many plasmids developed in the Core have been deposited to Addgene. There is no additional charge for standard packaging plasmids and helper viruses.